Part 1/9:
The Landscape of Biotechnology Investment
In the dynamic field of biotechnology, the thoughts from the CEO of Biogen on spending $3 billion on basic research over a decade raise compelling questions about investment strategy. Specifically, he remarked that this investment might have been better spent in venture funds, yielding profits if they diverted their resources to index investments like the S&P 500. This thinking invites investors to reconsider the traditional approaches to investing in biotechnology firms and suggest that passive investment strategies could sometimes outperform active research and development (R&D) efforts.